Joint survival analysis combining the methylation values and the expression levels of DMDGs indicated that genes with high expression levels (MDK, SERPINB1, NMNAT33, PARVB, and UPP1) were significantly associated with poor prognosis and had the potential to be therapeutic targets in GBM. The gene discussed is PARVB; the disease is glioblastoma.